Mark J. Ratain, M.D. joined the AspenBio Pharma Board of Directors in March 2008. At the University of Chicago, he holds the Leon O. Jacobson Professorship in Medicine and serves as Director of the Center for Personalized Therapeutics and Associate Director for Clinical Sciences for the Comprehensive Cancer Center. A hematologist/oncologist and clinical pharmacologist, Dr. Ratain has been affiliated with the University of Chicago Department of Medicine since 1983 and has authored and co-authored more than 350 articles and book chapters.
Prior to his board appointment at AspenBio, Dr. Ratain served as a director of DATATRAK International, Inc., a publicly traded company providing clinical trial services, from 1998 through 2008. Dr. Ratain earned his A.B. in Biochemical Sciences from Harvard University and his M.D. from Yale University School of Medicine.
Biography extracted from Riot PRE 14A filed 2011-06-01 View cached copy (2026-09-27)Live source ↗
Roles
Contiguous filings for the same role are collapsed into a single tenure span. Click a row to see the underlying filings.
| Company | Role | Tenure | Filings |
|---|---|---|---|
| Riot | Director | 2008-03 → present (18y 8mo) | 5 |
Show 5 underlying filings | |||
Insider transactions
Totals for this person
| Bucket | Invested (shares) | Invested (USD) | Divested (shares) | Divested (USD) | Net direction | Txns | Invested @ last price | Divested @ last price |
|---|---|---|---|---|---|---|---|---|
| All time | 160,000 | $0 | - | $0 | Flat | 4 | $2.05M | $0 |
| 2012 | 10,000 | $0 | - | $0 | Flat | 1 | $128.1K | $0 |
| 2011 | 50,000 | $0 | - | $0 | Flat | 1 | $640.5K | $0 |
| 2010 | 50,000 | $0 | - | $0 | Flat | 1 | $640.5K | $0 |
| 2009-Q1 | 50,000 | $0 | - | $0 | Flat | 1 | $640.5K | $0 |
| 2010-Q1 | 50,000 | $0 | - | $0 | Flat | 1 | $640.5K | $0 |
| 2011-Q1 | 50,000 | $0 | - | $0 | Flat | 1 | $640.5K | $0 |
| 2012-Q2 | 10,000 | $0 | - | $0 | Flat | 1 | $128.1K | $0 |
Invested = shares acquired (buys, grants, option exercises) — insider adding to the position. Divested = shares reduced (sells, dispositions, tax-withholding) — cash flowing TO the insider. Net direction shows which side wins on dollar terms in each bucket. % of holder's stake not yet computed (pending Form 3/4 holdings ingest). See methodology. The two @ last price columns restate the same share counts at the most recent share price we read (close of 2026-10-30); they are a valuation, not a cash flow, and they move every day the market does.
All transactions
| Date | Company | Kind | Shares | Amount (USD) | Value @ last price |
|---|---|---|---|---|---|
| 2012-04-02 | Riot | Grant / award / vesting · Stock Option (Right to Buy) | 10,000 | - | $128.1K |
| 2011-01-05 | Riot | Grant / award / vesting · Stock Option (Right to Buy) | 50,000 | - | $640.5K |
| 2010-01-19 | Riot | Grant / award / vesting · Option - Right to Buy | 50,000 | - | $640.5K |
| 2009-01-27 | Riot | Grant / award / vesting · Stock Option | 50,000 | - | $640.5K |